Polynucleotides encoding heavy and light chains of antibodies to OPGL

1. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14,

wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

2. The composition of claim 1 , wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule.

3. The composition of claim 1 , wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody.

4. The composition of claim 3 , wherein the single-chain antibody is a single-chain Fv antibody.

5. The composition of claim 1 , which encodes a Fab antibody.

6. The composition of claim 1 , which encodes a Fab′ antibody.

7. The composition of claim 1 , which encodes a F(ab′) 2 antibody.

8. The composition of claim 1 , which encodes a fully human antibody.

9. A vector comprising at least one polynucleotide selected from a first polynucleotide that encodes the amino acid sequence of SEQ ID NO: 13 and a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 14.

10. The vector of claim 9 , wherein the vector comprises at least one polynucleotide selected from a first polynucleotide that encodes the amino acid sequence of SEQ ID NO: 2 and a second polynucleotide that encodes the amino acid sequence of SEQ ID NO: 4.

11. A host cell comprising at least one vector of claim 9 .

12. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO: 14, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

13. The method of claim 12 , wherein the first polynucleotide encodes the amino acid sequence of SEQ ID NO: 2 and the second polynucleotide encodes the amino acid sequence of SEQ ID NO: 4.

14. The method of claim 12 , wherein the first polynucleotide encodes an amino acid sequence comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes an amino acid sequence comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

15. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 13 and the second polynucleotide encodes a light chain, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

16. The composition of claim 15 , wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467.

17. The composition of claim 15 , wherein the first polynucleotide encodes a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467.

18. The composition of claim 15 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14.

19. The composition of claim 16 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14.

20. The composition of claim 17 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14.

21. The composition of claim 15 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

22. The composition of claim 17 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

23. The composition of claim 15 , wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

24. The composition of claim 16 , wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

25. The composition of claim 15 , wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

26. The composition of claim 15 , wherein the first polynucleotide encodes a heavy chain consisting of the amino acid sequence as set forth in SEQ ID NO: 2 from residue 20 to residue 467, and the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

27. A composition comprising a first polynucleotide and a second polynucleotide, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO:14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

28. The composition of claim 27 , wherein the second polynucleotide encodes a light chain comprising the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

29. The composition of claim 27 , wherein the second polynucleotide encodes a light chain consisting of the amino acid sequence as set forth in SEQ ID NO: 4 from residue 21 to residue 235.

30. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:13 and the second polynucleotide encodes a light chain, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

31. A method of producing an antibody that interacts with OPGL, comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO: 14, and wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).

32. The method of claim 31 , wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence of SEQ ID NO: 13.

33. An antibody produced by the method of any one of claims 12 , and 30 , and 31 .

34. The composition of claim 15 or 27 , wherein the first polynucleotide and the second polynucleotide are part of the same nucleic acid molecule.

35. The composition of claim 15 or 27 , wherein the first polynucleotide and the second polynucleotide are operably linked such that they encode a single-chain antibody.

36. The composition of claim 35 , wherein the single-chain antibody is a single-chain Fv antibody.

37. The composition of claim 15 or 27 , which encodes a Fab antibody.

38. The composition of claim 15 or 27 , which encodes a Fab′ antibody.

39. The composition of claim 15 or 27 , which encodes a F(ab′) 2 antibody.

40. The composition of claim 15 or 27 , which encodes a fully human antibody.